<DOC>
	<DOCNO>NCT01704521</DOCNO>
	<brief_summary>This study examine viral dynamic response subject chronic hepatitis C hemophilia treat pegylated interferon + ribavirin telaprevir .</brief_summary>
	<brief_title>Viral Kinetics HCV Clearance Subjects With Hemophilia</brief_title>
	<detailed_description>Previous clinical trial treatment chronic hepatitis C exclude subject hemophilia participate .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Hemophilia A B 2 . HCV RNA positive ( PCR branchedchain DNA Methods ) , Genotype 1 ( a/b , mixed unknown subtype ) 3 . Chronic HCV infection evidence HCV serology , HCV RNA liver enzyme abnormality present least 6 month prior enrollment 4 . Liver biopsy noninvasive marker permit fibrosis stag within 12 month enrollment . If biopsy perform within 1 year , noninvasive marker may utilize screen period . Cirrhosis exclusion factor 5 . Age ≥ 18 year 6 . Prior HCV treatment naïve experience 7 . HCV viral load detectable screening period 8 . Absence exclusion criterion 9 . Sexually active subject ( male female ) must agree commit use medically acceptable form contraception duration study 6 month follow last dose study medication . Medically acceptable form contraception include oral contraceptive , injectable implantable method , intrauterine device properly use barrier contraception . 1 . Hemoglobin &lt; 11 2 . Pregnancy ( screen period time treatment ) 1. female , plan become pregnant breastfeed 2. male , whose partner pregnant planning become pregnant 3 . HIV Infection 4 . Prior History : 1 . Hepatitis B ( HBsAG negative must documentation negative result within one year prior enrollment screen period perform time window 2 . Homozygotic alpha1antitrypsin ( a1AT ) deficiency documentation a1AT level &lt; 80 ( anytime prior screen ) . If &lt; 80 , phenotype test demonstrate zz phenotype . All phenotype exclusionary , 3 . History Homozygotic Genetic Hemochromatosis ( anytime prior enrollment ) evidence iron overload require phlebotomy , 4 . Autoimmune marker ( antinuclear antibody ( ANA ) and/or antismooth muscle antibody ( ASMA ) ) &gt; 1:160 . 5 . Any significant liver disease process ( determine investigator ) . Nonalcoholic fattyliver disease ( NAFLD ) exclusion . 5 . History Decompensated liver disease evidence prior history hepatic encephalopathy ( Grade 2 high ) , ascites , variceal bleeding ; Platelet count &lt; 100,000 6 . Active thyroid disease ( OK thyroid replacement normal thyroidstimulating hormone ( TSH ) ; TSH abnormal must normal free thyroid index ) 7 . Chronic renal insufficiency , define creatinine clearance &lt; 50 ml/min . ( estimate Modification Diet Renal Disease ( MDRD ) formula ) 8 . Lifethreatening disease process could preclude completion trial opinion investigator . 9 . Any condition investigator feel preclude safe completion treatment regimen include severe psychiatric disorder , active alcohol recreational drug abuse . 10 . Inability provide inform consent . 11 . Use systemic corticosteroid immunomodulatory drug within 1 month ( Nasal steroids permit . ) 12 . Uncontrolled seizure disorder ( opinion investigator ) 13 . Concurrent autoimmune process active disease may exacerbate interferonbased therapy ( e.g . Crohn 's Disease , Rheumatoid arthritis ) opinion investigator . Psoriasis permit controlled topical medication time study enrollment . 14 . Use prohibit medication ( describe telaprevir package insert ) within 14 day first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Hemophilia</keyword>
</DOC>